Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Fenfluramine in Dravet Syndrome
2016-002804-14Phase 3Unknown
- Sponsor
- Zogenix, Inc.
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fenfluramine in Dravet syndrome, sponsored by Zogenix, Inc. Primary endpoints: Long-term safety and tolerability of fenfluramine and Effectiveness relative to pre-ZX008 baseline. Status: unknown.
02
Drugs
fenfluramine
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on 2016-002804-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002804-14.